MannKind Corporation (MNKD) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

MannKind Corporation (MNKD)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

6.03

-0.10 (-1.63%)

At close: Jan 14, 2025, 3:59 PM

6.02

-0.17%

After-hours Jan 14, 2025, 06:14 PM EST

undefined% (undefined)

Bid	5.79
Market Cap	1.66B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	0.08
PE Ratio (ttm)	75.38
Forward PE	n/a
Analyst	Buy

Ask	6.32
Volume	1,401,320
Avg. Volume (20D)	2,765,873
Open	6.23
Previous Close	6.13
Day's Range	6.00 - 6.32
52-Week Range	3.17 - 7.63
Beta	undefined

About MNKD

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocrinologists, and other healthcare providers for the treatment of hypothyroidism. The company has a licens...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Jul 28, 2004

Employees 411

Stock Exchange NASDAQ

Ticker Symbol MNKD

Website https://www.mannkindcorp.com

Analyst Forecast

According to 6 analyst ratings, the average rating for MNKD stock is "Buy." The 12-month stock price forecast is $8.5, which is an increase of 40.96% from the latest price.

Buy 100.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

MannKind Corporation is scheduled to release its earnings on Feb 25, 2025, during market hours.
Analysts project revenue of $75.06M, reflecting a 28.37% YoY growth and earnings per share of 0.03, making a 50.00% increase YoY.

Why Price Moved

3 weeks ago · Source

+8.73%

MannKind shares are trading higher after Wells Far... Unlock content with Pro Subscription

4 months ago · Source

+9.67%

MannKind shares are trading higher after Oppenheimer maintained an Outperform rating on the stock and raised its price target from $10 to $12.

News

4 weeks ago · seekingalpha.com

MannKind Corporation: A Speculative Buy On IPF And Diabetes Markets

MannKind Corporation is a biopharmaceutical company focused on inhaled therapies for endocrine and orphan lung diseases. MNKD's revenue growth is driven by Tyvaso DPI royalties and Afrezza expansion, ...

2 months ago · seekingalpha.com

MannKind Corporation (MNKD) Q3 2024 Earnings Conference Call Transcript

MannKind Corporation (NASDAQ:MNKD ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Michael Castagna - CEO Chris Prentiss - CFO Conference Call Participants Andreas A...

2 months ago · zacks.com

MannKind (MNKD) Reports Q3 Earnings: What Key Metrics Have to Say

The headline numbers for MannKind (MNKD) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street est...

2 months ago · zacks.com

MannKind (MNKD) Matches Q3 Earnings Estimates

MannKind (MNKD) came out with quarterly earnings of $0.04 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.02 per share a year ago.

2 months ago · zacks.com

MannKind Corporation (MNKD) Hits Fresh High: Is There Still Room to Run?

MannKind (MNKD) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.